answer text |
<p>NHS England has advised that its review of the national Cancer Drugs Fund (CDF)
list will ensure that more patients will be able to access drugs that provide better
outcomes for their cancers.</p><p> </p><p> </p><p> </p><p>This re-evaluation of some
CDF drugs, including regorafenib (Stivarga) for the treatment of gastrointestinal
stromal tumours, will mean that some patients who would have received the drugs to
be removed from the list will switch to alternative CDF drugs and the remainder will
be offered conventional treatments.</p><p> </p><p>NHS England has also assured the
Department that no patient whose treatment is currently being funded through the Fund
will have funding withdrawn, as long as it is clinically appropriate that they continue
to receive that treatment. In addition, no drug will be removed from the Fund where
it is the only therapy for that condition.</p><p> </p>
|
|